Financial Review: Clarus Therapeutics (OTCMKTS:CRXTQ) and Vaxcyte (NASDAQ:PCVX)

Clarus Therapeutics (OTCMKTS:CRXTQ) and Vaxcyte (NASDAQ:PCVX) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their valuation, analyst recommendations, earnings, risk, dividends, profitability and institutional ownership.

Profitability

This table compares Clarus Therapeutics and Vaxcyte’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Clarus Therapeutics	N/A	N/A	N/A
Vaxcyte	N/A	-28.83%	-26.89%

Valuation & Earnings

This table compares Clarus Therapeutics and Vaxcyte’s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Clarus Therapeutics	$13.96 million	N/A	-$40.62 million	N/A	N/A
Vaxcyte	N/A	N/A	-$402.27 million	($4.28)	-17.98

Clarus Therapeutics has higher revenue and earnings than Vaxcyte.

Analyst Recommendations

This is a summary of current recommendations and price targets for Clarus Therapeutics and Vaxcyte, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Clarus Therapeutics	0	0	0	0	N/A
Vaxcyte	0	0	4	0	3.00

Vaxcyte has a consensus price target of $78.50, indicating a potential upside of 2.71%. Given Vaxcyte’s higher probable upside, analysts plainly believe Vaxcyte is more favorable than Clarus Therapeutics.

Institutional & Insider Ownership

96.8% of Vaxcyte shares are held by institutional investors. 5.3% of Clarus Therapeutics shares are held by company insiders. Comparatively, 3.1% of Vaxcyte shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Summary

Clarus Therapeutics beats Vaxcyte on 5 of the 8 factors compared between the two stocks.

About Clarus Therapeutics

Clarus Therapeutics Holdings, Inc., a pharmaceutical company, focuses on the development and commercialization of oral testosterone replacement therapy in the United States. It offers JATENZO, a soft gel oral formulation of testosterone undecanoate for treating hypogonadal men. The company has a licensing agreement with HavaH Therapeutics for product to treat androgen therapies for inflammatory breast disease and certain forms of breast cancer; and license agreement with The Royal Institution for the Advancement of Learning/McGill University to develop and commercialize McGill's proprietary technology designed to treat conditions associated with CoQ10 deficiencies in humans. Clarus Therapeutics Holdings, Inc. was founded in 2003 and is based in Northbrook, Illinois.

About Vaxcyte

Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness. The company was formerly known as SutroVax, Inc. and changed its name to Vaxcyte, Inc. in May 2020. Vaxcyte, Inc. was incorporated in 2013 and is headquartered in San Carlos, California.